INVESTIGADORES
PUNTEL Mariana
congresos y reuniones científicas
Título:
Eradication of multifocal glioma in a syngeneic glioblastoma multiforme with Ad-Flt3L and Ad-HSV1-TK
Autor/es:
KING; MUHAMMAD; CURTIN; BARCIA; PUNTEL; LIU; HONIG; CANDOLFI; MONDKAR; LOWENSTEIN; CASTRO
Lugar:
Seattle, Washington, USA
Reunión:
Congreso; American Society of Gene Therapy; 2007
Resumen:
<!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:1;
mso-generic-font-family:roman;
mso-font-format:other;
mso-font-pitch:variable;
mso-font-signature:0 0 0 0 0 0;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;
mso-font-charset:0;
mso-generic-font-family:swiss;
mso-font-pitch:variable;
mso-font-signature:-1610611985 1073750139 0 0 159 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0in;
margin-right:0in;
margin-bottom:10.0pt;
margin-left:0in;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;
mso-fareast-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;
mso-fareast-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;
line-height:115%;}
@page Section1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;
mso-header-margin:.5in;
mso-footer-margin:.5in;
mso-paper-source:0;}
div.Section1
{page:Section1;}
-->
The disseminated nature of human glioblastoma multiforme (GBM)
makes at a particularlydifficult tumor to treat. We tested the hypothesis that
adenoviral (ad) mediated expression of Flt3L and HSV-tk within the GBM would
mediate regression of the primary treated tumor and a secondary, untreated
tumor growing at a distant site of the therapeutic vector injection. In either single
GBM or multifocal GBM models used, all saline treated animals succumbed to
tumors by day 22. Seventy percent of the animals bearing a single GBM mass
treated with AdFlt3L and AdTK survived long term. Fifty percent of the animals
bearing both a large primary GBM and a second GBM in the contralateral
hemisphere implanted at the time the primary tumor was being treated also
survived long term. Our results demonstrate that the combined therapy with AdFlt3l and AdTK can eradicate multifocal
brain tumor disease in a syngeneic, intracranial GBM model.
